Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2024.1468582 Oncology Correction Corrigendum: Shedding light on the shadows: oxidative stress and its pivotal role in prostate cancer progression Biesiadecki Marek 1 * Mołoń Mateusz 2 Balawender Krzysztof 1 Kobylińska Zofia 2 Galiniak Sabina 1 1 Institute of Medical Sciences, Rzeszów University, Rzeszów, Poland 2 Institute of Biology, Rzeszów University, Rzeszów, Poland

Edited and Reviewed by: Shafiq Khan, Clark Atlanta University, United States

*Correspondence: Marek Biesiadecki, mbiesiadecki@ur.edu.pl

20 08 2024 2024 14 1468582 22 07 2024 06 08 2024 Copyright © 2024 Biesiadecki, Mołoń, Balawender, Kobylińska and Galiniak 2024 Biesiadecki, Mołoń, Balawender, Kobylińska and Galiniak

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Shedding light on the shadows: oxidative stress and its pivotal role in prostate cancer progression By Biesiadecki M, Mołoń M, Balawender K, Kobylińska Z and Galiniak S (2024). Front. Oncol. 14:1393078. doi: 10.3389/fonc.2024.1393078 oxidative stress nitrosative stress oxidative damage of protein prostate cancer cancer progression section-in-acceptance Genitourinary Oncology

In the published article, there was an error in Tables 3 – 7 as published. The unit of serum Amadori products should be nmol/mg protein instead of μmol/mg protein. A typical unintentional editing mistake was made. The corrected Tables 3 – 7 appear below.

Markers of oxidative stress in healthy controls and patients with prostate cancer.

Healthy controls Prostate cancer group p
Serum AOPP (nmol/mg protein) 213.83 (192.02 − 291.16) 239.55 (195.37 − 425.47) 0.346
3-nitrotyrosine (nmol/mg protein) 0.116 (0.11 − 0.14) 0.119 (0.1 − 0.16) 0.748
Thiol groups (mmol/L) 643.92 (557.17 − 753.72) 573.87 (485.81 − 699.9) 0.044
Amadori products (nmol/mg protein) 1745.69 (1587.43 − 2176.05) 1987.22 (1826.28 − 2299.01) 0.031
TAC (ABTS•, μmol TE/L) 285.27 (271.48 − 294.88) 210.15 (201.85 − 217.55) <0.001
TAC (FRAP, μmol TE/L) 217.55 (184.24 − 237.92) 193.13 (168.65 − 225.12) 0.133
MDA (μmol) 3.27 (3.11 − 3.41) 3.56 (3.39 − 4.02) <0.001
4-HNE (pg/mL) 345.62 (238.01 − 508.88) 412.08 (301.17 − 487.3) 0.746
Urine AOPP (μmol/mmol creatinine) 12.72 (9.96 − 17.11) 14.87 (9.03 − 19.98) 0.538
Amadori products (mmol/mmol creatinine) 0.352 (0.28 − 0.48) 0.384 (0.31 − 0.54) 0.467
TAC (ABTS•, μmol TE/L) 856.83 (720.44 − 963.18) 758.85 (573.7 − 1026.94) 0.194
TAC (FRAP, μmol TE/L) 564.90 (448.23 − 625.55) 451.44 (297.01 − 638.48) 0.047
MDA (μmol/mmol creatinine) 0.86 (0.71 − 1.01) 1.15 (0.96 − 1.34) <0.001

Markers of oxidative stress in patients divided in groups considering the cancer stage depending on the TNM classification.

T1 T2 T3 p
Serum AOPP (nmol/mg protein) 238.35 219.40 378.77 0.123
3-nitrotyrosine (nmol/mg protein) 0.137 0.117 0.113 0.941
Thiol groups (mmol/L) 699.59 564.23 436.08 0.011
Amadori products (nmol/mg protein) 1865.81 1996.79 2064.07 0.719
TAC (ABTS•, μmol TE/L) 220.32 214.61 198.77 <0.001
TAC (FRAP, μmol TE/L) 223.62 195.48 160.32 <0.001
MDA (μmol) 3.39 3.56 4.31 0.001
4-HNE (pg/mL) 246.9 417.42 508.19 0.002
Urine AOPP (μmol/mmol creatinine) 12.21 17.83 15.37 0.594
Amadori products (mmol/mmol creatinine) 0.384 0.357 0.382 0.405
TAC (ABTS•, μmol TE/L) 763.28 696.62 959.94 0.589
TAC (FRAP, μmol TE/L) 462 377.24 635.39 0.464
MDA (μmol/mmol creatinine) 0.829 1.146 1.191 0.026

Markers of oxidative stress in patients divided in groups considering Gleason grading system.

<7 7 >7 p
Serum AOPP (nmol/mg protein) 238.35 208.52 528.53 0.02
3-nitrotyrosine (nmol/mg protein) 0.115 0.117 0.125 0.678
Thiol groups (mmol/L) 700.81 555.68 488.69 0.002
Amadori products (nmol/mg protein) 1829.38 2202.23 1962.49 0.086
TAC (ABTS•, μmol TE/L) 215.74 215.24 198.77 <0.001
TAC (FRAP, μmol TE/L) 207.85 216.93 166.00 0.007
MDA (μmol) 3.40 3.42 4.01 0.077
4-HNE (pg/mL) 258.68 417.42 527.98 <0.001
Urine AOPP (μmol/mmol creatinine) 12.65 14.02 19.98 0.245
Amadori products (mmol/mmol creatinine) 0.433 0.356 0.392 0.405
TAC (ABTS•, μmol TE/L) 942.11 607.90 727.74 0.314
TAC (FRAP, μmol TE/L) 634.48 446.00 498.74 0.70
MDA (μmol/mmol creatinine) 0.853 1.174 1.306 0.054

Markers of oxidative stress in patients divided in groups considering the cancer histological grade.

G1 G2 p
Serum AOPP (nmol/mg protein) 221.08 295.95 0.191
3-nitrotyrosine (nmol/mg protein) 0.124 0.113 0.623
Thiol groups (mmol/L) 623.49 555.31 0.37
Amadori products (nmol/mg protein) 1982.92 2021.04 0.696
TAC (ABTS•, μmol TE/L) 212.51 205.67 0.004
TAC (FRAP, μmol TE/L) 220.27 166.01 <0.001
MDA (μmol) 3.39 4.03 <0.001
4-HNE (pg/mL) 390.8 474.68 0.124
Urine AOPP (μmol/mmol creatinine) 14.43 19.97 0.999
Amadori products (mmol/mmol creatinine) 0.321 0.382 0.049
TAC (ABTS•, μmol TE/L) 728.12 912.93 0.731
TAC (FRAP, μmol TE/L) 320.11 631.82 0.023
MDA (μmol/mmol creatinine) 0.97 1.34 0.005

Markers of oxidative stress in patients divided in groups considering the presence of perineural invasion.

Absent of perineural invasion Presence of perineural invasion p
Serum AOPP (nmol/mg protein) 219.36 277.59 0.346
3-nitrotyrosine (nmol/mg protein) 0.114 0.134 0.603
Thiol groups (mmol/L) 542.56 586.98 0.223
Amadori products (nmol/mg protein) 1962.49 2092.05 0.19
TAC (ABTS•, μmol TE/L) 215.63 208.95 0.154
TAC (FRAP, μmol TE/L) 207.92 176.32 0.036
MDA (μmol) 3.52 3.84 0.147
4-HNE (pg/mL) 326.92 453.66 0.102
Urine AOPP (μmol/mmol creatinine) 10.63 22.56 <0.001
Amadori products (mmol/mmol creatinine) 0.356 0.388 0.89
TAC (ABTS•, μmol TE/L) 998.71 694.79 0.063
TAC (FRAP, μmol TE/L) 638.48 296.42 <0.001
MDA (μmol/mmol creatinine) 1.11 1.19 0.452

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.